A Clinical Trial to Evaluate the Safety and Pharmacokinetic

Exclusion Criteria

• •1. A clinically significant disease or history in hepatobiliary system, kidney, digestive system, respiratory system, hemato-oncological system, endocrine system, neuro-psychiatric system, musculo-skeletal system, immune system, otorhinolaryngological system or cardiovascular system.
• •2. A history of hypersensitivity to investigational drugs and its additives or clinically significant hypersensitivity to any other drug.
• •3. History of drug abuse, or positive in drug screening test.
• •4. Use of inducer or inhibitor of metabolic enzymes for drugs like barbiturate.
• •5. Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to the first administration of investigational drug, and this will affect this study or the safety of the subjects at discretion of study investigator.
• •6. Participation in another clinical trial or a bioequivalent study within 3 months prior to the first administration of investigational drug (The finish time of previous study is the day of the last administration of study drug)
• •7. Whole blood donation within 2 months or component donation within 1 month, prior to the first administration of investigational drug, or transfusion within 1 month prior to the first administration of investigational drug.
• •8. Prolonged excessive alcohol consumption (\>21 units/week, 1 unit=10g of pure alcohol), or subjects who can not abstain from drinking from 24 hours prior to hospitalization until the discharge.
• •9. Smoking more than 10 cigarettes per day, excessive caffeine consumption (example: instant coffee \> 5 cups/day)
• •10. Subjects who are judged to be inappropriate for this study by investigators according to other reasons including clinical lab test result